Head and Neck Cancer
Conditions
Brief summary
The primary objective of this study is to describe, in detail, patterns of care for head and neck carcinoma patient
Interventions
OTHERTherapy for head and neck cancer
radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
Sponsors
Eli Lilly and Company
Study design
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Pathologically (histologically or cytologically) confirmed new diagnosis of carcinoma involving the oral cavity, oropharynx, nasopharynx, hypopharynx, larynx, or neck node metastasis from unknown origin * Scheduled to receive radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy * Written informed consent
Exclusion criteria
* Registry participation does not exclude participation in clinical trials. * Patients scheduled to receive or who have received surgery are eligible for Registry participation as long as they are also scheduled to receive medical therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Patterns of care for head and neck cancer | up to 10 years |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival by treatment regimen | study entry to death from any cause or to end of study |
| Determine the incidence and severity of major dose-limiting and other important treatment toxicities | up to 10 years |
| Identify supportive care received for managing nutrition, pain, nausea and other complications | up to 10 years |
| tumor control by treatment regimen | study entry to progressive disease |
Countries
United States
Outcome results
None listed